Heart failure (HF) is a highly prevalent cardiovascular condition in people over 65 years old [1]. Mortality associated with HF decompensations (acute HF; AHF) is high, with 30-day and 1-year all-cause mortality surpassing 10 % and 30 %, respectively [2-4]. In addition, an increased risk of adverse events occurs during the vulnerable phase, i.e., the weeks after patient discharge from the hospital due to an AHF episode [5,6]. Some of these adverse events have been related to remaining congestion at discharge as well as decreased effectiveness of loop diuretics once patients are discharged home.
